PL402986A1 - Pochodna eteru alkilowego lub jej sól, stanowiaca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól - Google Patents

Pochodna eteru alkilowego lub jej sól, stanowiaca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól

Info

Publication number
PL402986A1
PL402986A1 PL402986A PL40298602A PL402986A1 PL 402986 A1 PL402986 A1 PL 402986A1 PL 402986 A PL402986 A PL 402986A PL 40298602 A PL40298602 A PL 40298602A PL 402986 A1 PL402986 A1 PL 402986A1
Authority
PL
Poland
Prior art keywords
salt
benzothiophen
ethoxy
propyl
azetydynol
Prior art date
Application number
PL402986A
Other languages
English (en)
Other versions
PL217872B1 (pl
Inventor
Akihito Saitoh
Noboru Iwakami
Tamotsu Takamatsu
Original Assignee
Toyama Chemical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd filed Critical Toyama Chemical Co., Ltd
Publication of PL402986A1 publication Critical patent/PL402986A1/pl
Publication of PL217872B1 publication Critical patent/PL217872B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Przedmiotem wynalazku jest 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól.
PL402986A 2001-10-19 2002-10-18 Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól PL217872B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001321381 2001-10-19

Publications (2)

Publication Number Publication Date
PL402986A1 true PL402986A1 (pl) 2013-04-29
PL217872B1 PL217872B1 (pl) 2014-08-29

Family

ID=19138603

Family Applications (2)

Application Number Title Priority Date Filing Date
PL369601A PL215264B1 (pl) 2001-10-19 2002-10-18 Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna
PL402986A PL217872B1 (pl) 2001-10-19 2002-10-18 Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL369601A PL215264B1 (pl) 2001-10-19 2002-10-18 Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna

Country Status (23)

Country Link
US (4) US7087594B2 (pl)
EP (1) EP1437353B1 (pl)
JP (1) JP4398247B2 (pl)
KR (1) KR100956990B1 (pl)
CN (2) CN100500662C (pl)
AT (1) ATE364604T1 (pl)
AU (1) AU2002344107B2 (pl)
BR (1) BRPI0213393B8 (pl)
CA (1) CA2464358C (pl)
CY (1) CY1106714T1 (pl)
DE (1) DE60220694T2 (pl)
DK (1) DK1437353T3 (pl)
ES (1) ES2287324T3 (pl)
HU (1) HU230407B1 (pl)
IL (2) IL161308A0 (pl)
MX (1) MXPA04003541A (pl)
NO (1) NO325780B1 (pl)
NZ (1) NZ532328A (pl)
PL (2) PL215264B1 (pl)
PT (1) PT1437353E (pl)
RO (1) RO122203B1 (pl)
WO (1) WO2003035647A1 (pl)
ZA (1) ZA200402806B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1437353E (pt) * 2001-10-19 2007-08-28 Toyama Chemical Co Ltd Derivados de éter de alquilo ou os seus sais.
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
MXPA05011125A (es) * 2003-04-17 2005-12-14 Toyama Chemical Co Ltd Remedio preventivo para enfermedades del nervio retiniano que contienen derivados de eter de alquilo o sales de los mismos.
AU2011204959B2 (en) * 2005-03-28 2012-04-12 Toyama Chemical Co., Ltd. Process for production of 1-(3-(2-(1-benzothiophen-5-YL)- ethoxy)propyl)azetidin-3-ol or salts thereof
PL2210884T3 (pl) * 2005-03-28 2012-07-31 Toyama Chemical Co Ltd Proces wytwarzania kwasu 3-(2-(1-benzotiofen-5-ylo)etoksy)propionowego lub jego soli
RU2397169C2 (ru) * 2005-03-28 2010-08-20 Тояма Кемикал Ко., Лтд. Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
JP4902247B2 (ja) * 2005-04-08 2012-03-21 富山化学工業株式会社 ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
JP2006328058A (ja) * 2005-04-27 2006-12-07 Toyama Chem Co Ltd ２−（１−ベンゾチオフェン−５−イル）エタノールの新規製造法およびその中間体
PT2011796E (pt) * 2006-04-26 2014-11-26 Toyama Chemical Co Ltd Indutor de neurogénese ou agente terapêutico utilizado em neuropatias que compreende um derivado de um éter alquílico ou um seu sal
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
KR20090038471A (ko) * 2006-08-04 2009-04-20 토야마 케미칼 컴퍼니 리미티드 알킬에테르 유도체 또는 그 염을 함유하는 프로테인키나제 ｃ 활성촉진제
ES2465005T3 (es) * 2008-05-28 2014-06-04 Toyama Chemical Co., Ltd. Derivado de óxido de benzotiofeno y sus sales
JP6054940B2 (ja) 2012-02-22 2016-12-27 富山化学工業株式会社 １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含有する固形医薬組成物
ES2792950T3 (es) 2014-01-31 2020-11-12 Fujifilm Toyama Chemical Co Ltd Agente potenciador del efecto de rehabilitación después de una lesión nerviosa que comprende un derivado alquil éter o una sal del mismo
JP6761413B2 (ja) * 2015-06-11 2020-09-23 富士フイルム富山化学株式会社 シグマ受容体結合剤
JP6860502B2 (ja) 2015-12-25 2021-04-14 富士フイルム富山化学株式会社 １−（３−（２−（１−ベンゾチオフェン−５−イル）エトキシ）プロピル）アゼチジン−３−オールまたはその塩を含む錠剤
US10849880B2 (en) 2016-12-28 2020-12-01 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition
EP3563846B1 (en) 2016-12-28 2023-07-19 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition and method for producing the same
EP3563847B1 (en) 2016-12-28 2023-09-20 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
US20190343796A1 (en) * 2016-12-28 2019-11-14 Fujifilm Toyama Chemical Co., Ltd. Composition for external use
CN116473962A (zh) * 2017-06-02 2023-07-25 富士胶片富山化学株式会社 脑萎缩预防或治疗剂
JP7370859B2 (ja) 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
CN110691595A (zh) 2017-06-02 2020-01-14 富士胶片富山化学株式会社 β-淀粉样蛋白量减少剂
JP7133547B2 (ja) 2017-06-02 2022-09-08 富士フイルム富山化学株式会社 脊髄小脳変性症予防または治療剤
WO2019088083A1 (ja) 2017-10-30 2019-05-09 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
CN114853619B (zh) * 2022-05-19 2024-05-10 神隆医药（常熟）有限公司 一种适于工业化生产的n-甲基酪胺盐酸盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156973A (ja) 1987-09-04 1989-06-20 Tanabe Seiyaku Co Ltd ベンゾフラン誘導体
JP2887492B2 (ja) 1990-02-05 1999-04-26 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP3044055B2 (ja) 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
DK74693D0 (da) 1993-06-23 1993-06-23 Novo Nordisk As Novel heterocyclic chemistry
JP3232830B2 (ja) 1993-11-30 2001-11-26 三菱電機株式会社 フレキシブルディスク装置のキャリッジ機構
KR100447738B1 (ko) 1994-10-25 2005-09-20 도야마 가가쿠 고교 가부시키가이샤 1,2-에탄디올유도체또는그의염을함유한의약조성물
JPH08268883A (ja) 1994-10-25 1996-10-15 Toyama Chem Co Ltd １−フェニル−１，２−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤
CZ296236B6 (cs) 1995-08-11 2006-02-15 Pfizer Inc. Trihydrát methansulfonátu (1S,2S)-1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu, farmaceutický prostredek a farmaceutická kombinace s jeho obsahem
EP0873990A1 (en) 1995-09-22 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
DE19605610A1 (de) 1996-02-15 1997-08-21 Hoechst Ag Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1997030703A1 (en) 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof
JP4549452B2 (ja) 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
WO1999031056A1 (en) * 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
US6797726B1 (en) 1999-06-11 2004-09-28 Toyama Chemical Co., Ltd. N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same
PT1437353E (pt) 2001-10-19 2007-08-28 Toyama Chemical Co Ltd Derivados de éter de alquilo ou os seus sais.
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
MXPA05011125A (es) 2003-04-17 2005-12-14 Toyama Chemical Co Ltd Remedio preventivo para enfermedades del nervio retiniano que contienen derivados de eter de alquilo o sales de los mismos.
PL2210884T3 (pl) 2005-03-28 2012-07-31 Toyama Chemical Co Ltd Proces wytwarzania kwasu 3-(2-(1-benzotiofen-5-ylo)etoksy)propionowego lub jego soli
PT2011796E (pt) 2006-04-26 2014-11-26 Toyama Chemical Co Ltd Indutor de neurogénese ou agente terapêutico utilizado em neuropatias que compreende um derivado de um éter alquílico ou um seu sal
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
KR20090038471A (ko) 2006-08-04 2009-04-20 토야마 케미칼 컴퍼니 리미티드 알킬에테르 유도체 또는 그 염을 함유하는 프로테인키나제 ｃ 활성촉진제
ES2465005T3 (es) 2008-05-28 2014-06-04 Toyama Chemical Co., Ltd. Derivado de óxido de benzotiofeno y sus sales

Also Published As

Publication number Publication date
EP1437353A1 (en) 2004-07-14
US20050070521A1 (en) 2005-03-31
JP4398247B2 (ja) 2010-01-13
BR0213393A (pt) 2005-01-11
RO122203B1 (ro) 2009-02-27
WO2003035647A1 (en) 2003-05-01
MXPA04003541A (es) 2004-07-22
US7087594B2 (en) 2006-08-08
HUP0500017A3 (en) 2011-07-28
USRE43676E1 (en) 2012-09-18
PL215264B1 (pl) 2013-11-29
CN101643470A (zh) 2010-02-10
KR20040050919A (ko) 2004-06-17
CA2464358C (en) 2011-05-24
CN101643470B (zh) 2012-08-01
CA2464358A1 (en) 2003-05-01
JPWO2003035647A1 (ja) 2005-07-28
IL161308A (en) 2011-06-30
CN100500662C (zh) 2009-06-17
PL217872B1 (pl) 2014-08-29
HUP0500017A2 (hu) 2005-04-28
DE60220694T2 (de) 2008-02-07
ES2287324T3 (es) 2007-12-16
PL369601A1 (pl) 2005-05-02
NO325780B1 (no) 2008-07-14
US20090111992A1 (en) 2009-04-30
PT1437353E (pt) 2007-08-28
ZA200402806B (en) 2005-06-29
EP1437353A4 (en) 2005-01-19
EP1437353B1 (en) 2007-06-13
IL161308A0 (en) 2004-09-27
AU2002344107B2 (en) 2007-11-01
NZ532328A (en) 2005-07-29
CY1106714T1 (el) 2012-05-23
CN1571786A (zh) 2005-01-26
NO20041531L (no) 2004-04-15
US20060194781A1 (en) 2006-08-31
DK1437353T3 (da) 2007-08-06
US7468443B2 (en) 2008-12-23
HU230407B1 (hu) 2016-04-28
US8129535B2 (en) 2012-03-06
ATE364604T1 (de) 2007-07-15
DE60220694D1 (de) 2007-07-26
BRPI0213393B1 (pt) 2018-12-04
BRPI0213393B8 (pt) 2021-05-25
KR100956990B1 (ko) 2010-05-11

Similar Documents

Publication Publication Date Title
PL402986A1 (pl) Pochodna eteru alkilowego lub jej sól, stanowiaca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól
GB0124627D0 (en) Novel compounds
EA200300429A1 (ru) Способ получения порошковых композиций
HN2000000265A (es) COMPUESTOS DE PIRROLO (2,3d) PIRIMIDINA
CO5550395A2 (es) Antranilamidas artropodicidas
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
BR0207983A (pt) Inibidores de metaloproteinase
PL368370A1 (pl) Kompozycja glifosatu
EP1734101A4 (en) COOLING MACHINE OIL COMPOSITION
DK1370633T3 (da) Smöremiddelsammensætning
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
EP1337145A4 (en) NON-WATER INSECT-DRIPPING COMPOSITION
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
BR0214378A (pt) Composições herbicidas contendo benzoilpirazóis e protetores
MEP13608A (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
DE60229420D1 (de) Neue metallproteinaseinhibitoren
DK1651913T3 (da) Köleskab
EP1526170A4 (en) OIL COMPOSITION
PA8543701A1 (es) Fenil-heterociclil-eteres
CR7962A (es) Clorhidrato de 1-(4-(2-piperidiniletoxi) Fenoxi)-2-(-4Metanosulfonifenil)-6-Hidroxinaftaleno Cristalino no solvatado
BRPI0416678A (pt) pirazolpirimidinas
ITTO20010051A0 (it) Dispositivo di alimentazione dell'olio per un compressore alternativoracchiuso.
MXPA02012400A (es) Heterociclos hetaril-substituidos.
DK1255745T3 (da) Syntese af vandoplöseligt 9-dihydro-paclitaxel afledninger fra 9-dihydro-13-acetylbaccatin III